This new facility integrates multi-channel chip, micro-mixer system, and complex preparation system into a multi-channel micro-mixer core LNP manufacturing platform
Investment further strengthens Merck's "Big 3," the key drivers for increasing Group sales to approximately € 25 billion by 2025
SK Capital’s investment will serve as a catalyst for a new strategic direction as the Company seeks to deepen and expand its presence in fine chemistries for the global life science market.
Her appointment further strengthens the CDMO’s strategy to become the nutraceutical R&D hub for brands looking for agile partners with large scientific and development resources
Under the terms of the agreement, Lonza can now provide its customers with seamless access to Touchlight’s enzymatic DNA technology
Proceeds from the proposed issue will be utilized to part finance Balaxi’s planned EU GMP-compliant manufacturing facility for Oral Solid Dosages and Liquid Injectables at TSIIC Pharma Formulations SEZ
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
Dr. Mahdavi will lead Ginkgo's commercial efforts in the growing areas of bio-reagents, cell and gene therapies and new biopharmaceutical modalities.
The capital expansion program commenced in June 2022 and is expected to complete in 2024
Subscribe To Our Newsletter & Stay Updated
